期刊文献+

降糖药二甲双胍对甲状腺未分化癌细胞增殖及凋亡的作用 被引量:7

Effect of metformin on proliferation and apoptosis of human anaplastic thyroid carcinoma cells
下载PDF
导出
摘要 目的:研究二甲双胍对甲状腺未分化癌细胞增殖及凋亡的作用,初步探讨其作用机制。方法:以不同浓度二甲双胍作用于未分化癌SW1736细胞,MTT法检测其增殖,流式细胞术检测细胞周期和凋亡情况。结果:二甲双胍可显著抑制SW1736细胞增殖,其抑制作用呈剂量依赖性,并随着作用时间的延长抑制作用逐渐增强,于72 h达到最大抑制效果。流式细胞检测结果显示二甲双胍可阻滞未分化癌细胞周期至G0/G1期;并可促进肿瘤细胞凋亡,随着二甲双胍作用浓度的递增,肿瘤细胞的凋亡率逐渐增加,20 mmol/L二甲双胍作用48 h后,可使SW1736细胞凋亡率从8.3%增加至13.3%,与对照组相比,有显著统计学差异。结论:二甲双胍可抑制甲状腺未分化癌细胞的增殖活性,阻滞细胞周期进程,诱导细胞凋亡,为甲状腺未分化癌的治疗研究提供了新的方向。 Objective:To investigate the effect of metformin on proliferation and apoptosis of human anaplastic thyroid carcinoma cells, and explore the underlying mechanisms. Methods: Human anaplastic thyroid cancer cell line SW1736 was treated with different doses of metformin. MTF assay was used to detect proliferation viability of cell line. Cell cycle progression and apoptosis were analyzed by flow cytometry. Results:Metformin significantly inhibited the growth of SW1736 cells in time- and dose-dependent manner with a maximal effect at 72 h. The results of flow eytometry showed that anaplastie cancer cell cycle was arrested to G0/G1 phase by metformin. Furthermore,metformin also enhanced apoptosis of SW1736 cells in a dose-dependent manner. Compared with the control group,addition of 20 mmol/L metformin for 48 h increased the percentage of apoptotic cells from 8.3% to 13.3% in SW1736 cells. Conclusion:Metformin can inhibit proliferation and cell cycle progression and induce apoptosis of thyroid carcinoma cell line. Therefore,it may be a potential therapeutic agent for the treatment of human anaplastic thyroid carcinoma.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2014年第4期442-445,451,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金(81102032)
关键词 二甲双胍 甲状腺癌 增殖 凋亡 metformin thyroid carcinoma proliferation apoptosis
  • 相关文献

参考文献1

二级参考文献1

共引文献12

同被引文献56

  • 1黄晓净,王志峰,韩丹丹,杜志兴,庞建民.健康人群口服二甲双胍预防肿瘤机制探讨[J].中国误诊学杂志,2019,0(8):381-384. 被引量:2
  • 2张宗敏,徐震纲,唐平章,薛丽燕,吕宁.重新认识甲状腺未分化癌[J].中国医学科学院学报,2006,28(3):322-324. 被引量:10
  • 3Kalemkerian GP,Akerley W, B ogner P,et al. Small cel lung cancer[J ].J Nat Compr Cane Netw, 2013,11 ( 1 ) : 78-98.
  • 4Birsoy K. Possemato R. Lorbeer FK. et al. Metabolic de- terminants of cancer cell sensitivity to glucose limitation and biguanides[J]. Nature,2014,508(7494) : 108-112.
  • 5Hsieh MC,Lee TC,Cheng SM,et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwan Residents[J]. Exp Diabetes Res,2012,doi: 10.1155/ 2012/413782.
  • 6Libby G,Donnelly LA,Donnan PT,et al. New users of mefforrnin are at low risk of incident eaneer:a cohort study among people with type 2 diabetes[J]. Diabetes Care, 2009,32(9) : 1620-1625.
  • 7Mazzone PJ,Rai H,Beukemann M,et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics[J]. BMC Cancer,2012,14(12) :410.
  • 8Smiechowski BB,Azoulay L,Yin H,et al. The use of met- formin and the incidence of lung cancer in patients with type 2 diabetes[J].Diabetes Care, 2013,36( 1 ) : 124-129.
  • 9Zhang ZJ,Bi Y,Li S,et al. Reduced risk of lung cancer with metformin therapy in diabetic patients:A systematic review and meta-analysis[J]. Am J Epidemiol,2014,180(1) : 11-14.
  • 10Bryan T. Oronsky,Neil Oronsky,Gary R. Fanger,Christopher W. Parker,Scott Z. Caroen,Michelle Lybeck,Jan J. Scicinski.??Follow the ATP: Tumor Energy Production: A Perspective(J)Anti-Cancer Agents in Medicinal Chemistry . 2014 (9)

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部